• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Similar patterns of chromosome abnormalities in CML occur in addition to the Philadelphia chromosome with or without tyrosine kinase inhibitor treatment.

作者信息

Haferlach C, Bacher U, Schnittger S, Weiss T, Kern W, Haferlach T

出版信息

Leukemia. 2010 Mar;24(3):638-40. doi: 10.1038/leu.2009.222. Epub 2009 Oct 29.

DOI:10.1038/leu.2009.222
PMID:19865111
Abstract
摘要

相似文献

1
Similar patterns of chromosome abnormalities in CML occur in addition to the Philadelphia chromosome with or without tyrosine kinase inhibitor treatment.除费城染色体外，慢性粒细胞白血病中类似的染色体异常模式也会出现，无论是否接受酪氨酸激酶抑制剂治疗。
Leukemia. 2010 Mar;24(3):638-40. doi: 10.1038/leu.2009.222. Epub 2009 Oct 29.
2
Additional chromosome abnormalities, BCR-ABL tyrosine kinase domain mutations and clinical outcome in Hungarian tyrosine kinase inhibitor-resistant chronic myelogenous leukemia patients.匈牙利酪氨酸激酶抑制剂耐药慢性髓性白血病患者的附加染色体异常、BCR-ABL 酪氨酸激酶结构域突变和临床结局。
Acta Haematol. 2012;127(1):34-42. doi: 10.1159/000331472. Epub 2011 Oct 14.
3
Low or undetectable numbers of Philadelphia chromosome-positive leukemic stem cells (Ph(+)CD34(+)CD38(neg)) in chronic myeloid leukemia patients in complete cytogenetic remission after tyrosine kinase inhibitor therapy.在接受酪氨酸激酶抑制剂治疗后处于完全细胞遗传学缓解期的慢性髓性白血病患者中，费城染色体阳性白血病干细胞（Ph(+)CD34(+)CD38(neg)）数量低或检测不到
Leukemia. 2010 Jan;24(1):219-22. doi: 10.1038/leu.2009.190. Epub 2009 Sep 24.
4
Applying the discovery of the Philadelphia chromosome.应用费城染色体的发现。
J Clin Invest. 2007 Aug;117(8):2067-74. doi: 10.1172/JCI31988.
5
[Imatinib therapy for patients with chronic myelogenous leukemia].伊马替尼治疗慢性粒细胞白血病患者
Gan To Kagaku Ryoho. 2005 Mar;32(3):297-303.
6
Early in vivo changes of the transcriptome in Philadelphia chromosome-positive CD34+ cells from patients with chronic myelogenous leukaemia following imatinib therapy.伊马替尼治疗后慢性髓性白血病患者费城染色体阳性CD34+细胞转录组的早期体内变化。
Leukemia. 2009 May;23(5):983-5. doi: 10.1038/leu.2008.337. Epub 2008 Dec 4.
7
CML resistance to tyrosine kinase inhibitors: how is the laboratory to tell?慢性粒细胞白血病对酪氨酸激酶抑制剂的耐药性：实验室如何判定？
Lab Hematol. 2004;10(3):181-4.
8
Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome.BCR-ABL酪氨酸激酶特异性抑制剂在伴有费城染色体的慢性髓性白血病急变期和急性淋巴细胞白血病中的活性
N Engl J Med. 2001 Apr 5;344(14):1038-42. doi: 10.1056/NEJM200104053441402.
9
Chromosome abnormalities additional to the Philadelphia chromosome at the diagnosis of chronic myelogenous leukemia: pathogenetic and prognostic implications.慢性髓性白血病诊断时除费城染色体外的染色体异常：发病机制及预后意义
Cancer Genet Cytogenet. 2010 Jun;199(2):76-80. doi: 10.1016/j.cancergencyto.2010.02.003.
10
Sustained, clonal karyotype abnormalities in the Philadelphia chromosome negative cells of CML patients successfully treated with Imatinib.
Leukemia. 2003 Feb;17(2):465-7. doi: 10.1038/sj.leu.2402791.

引用本文的文献

1
Prolonged unfolded protein reaction is involved in the induction of chronic myeloid leukemia cell death upon oprozomib treatment.持续未折叠蛋白反应参与了奥普佐米治疗慢性髓性白血病细胞死亡的诱导。
Cancer Sci. 2021 Jan;112(1):133-143. doi: 10.1111/cas.14696. Epub 2020 Nov 12.
2
Coexistence of recurrent chromosomal abnormalities and the Philadelphia chromosome in acute and chronic myeloid leukemias: report of five cases and review of literature.急性和慢性髓系白血病中复发性染色体异常与费城染色体的共存：5例报告及文献复习
Mol Cytogenet. 2020 Aug 19;13:34. doi: 10.1186/s13039-020-00501-6. eCollection 2020.
3
Additional chromosomal abnormalities in Philadelphia positive chronic myeloid leukemia.
费城染色体阳性慢性髓性白血病中的额外染色体异常
Pak J Med Sci. 2020 Jan-Feb;36(2):208-212. doi: 10.12669/pjms.36.2.1384.
4
Clinical and prognostic significance of 3q26.2 and other chromosome 3 abnormalities in CML in the era of tyrosine kinase inhibitors.酪氨酸激酶抑制剂时代慢性髓性白血病中3q26.2及其他3号染色体异常的临床及预后意义
Blood. 2015 Oct 1;126(14):1699-706. doi: 10.1182/blood-2015-05-646489. Epub 2015 Aug 4.
5
Chromosomal rearrangement involving 11q23 locus in chronic myelogenous leukemia: a rare phenomenon frequently associated with disease progression and poor prognosis.慢性粒细胞白血病中涉及11q23位点的染色体重排：一种罕见现象，常与疾病进展和预后不良相关。
J Hematol Oncol. 2015 Apr 8;8:32. doi: 10.1186/s13045-015-0128-2.
6
Genomic instability may originate from imatinib-refractory chronic myeloid leukemia stem cells.基因组不稳定性可能源于对伊马替尼耐药的慢性髓性白血病干细胞。
Blood. 2013 May 16;121(20):4175-83. doi: 10.1182/blood-2012-11-466938. Epub 2013 Mar 29.
7
Prognostic importance of additional cytogenetic anomalies in chronic myeloid leukemia.慢性髓性白血病中附加细胞遗传学异常的预后意义。
Med Oncol. 2013 Mar;30(1):443. doi: 10.1007/s12032-012-0443-1. Epub 2013 Jan 5.
8
Rac2-MRC-cIII-generated ROS cause genomic instability in chronic myeloid leukemia stem cells and primitive progenitors.Rac2-MRC-cIII 产生的 ROS 导致慢性髓性白血病干细胞和原始祖细胞的基因组不稳定。
Blood. 2012 May 3;119(18):4253-63. doi: 10.1182/blood-2011-10-385658. Epub 2012 Mar 12.
9
Genetic mechanisms of chronic myeloid leukemia blastic transformation.慢性髓性白血病原始细胞危象的遗传机制。
Curr Hematol Malig Rep. 2012 Jun;7(2):87-93. doi: 10.1007/s11899-012-0114-5.
10
Targeting RAD51 phosphotyrosine-315 to prevent unfaithful recombination repair in BCR-ABL1 leukemia.针对 RAD51 磷酸酪氨酸-315 以防止 BCR-ABL1 白血病中的不忠实重组修复。
Blood. 2011 Jul 28;118(4):1062-8. doi: 10.1182/blood-2010-09-307256. Epub 2011 Jun 7.